STOCK TITAN
  1. Home
  2. News
  3. RIGL

Rigel Pharmaceuticals - RIGL STOCK NEWS

Welcome to our dedicated news page for Rigel Pharmaceuticals (Ticker: RIGL), a resource for investors and traders seeking the latest updates and insights on Rigel Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Rigel Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Rigel Pharmaceuticals's position in the market.

News
Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA® (Olutasidenib) in AML and Other Cancers
Rhea-AI Summary
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and The University of Texas MD Anderson Cancer Center (MD Anderson) have announced a strategic development collaboration to expand the evaluation of REZLIDHIA® (olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. REZLIDHIA is a potent, selective, oral, small-molecule inhibitor of mutated IDH1 (mIDH1) designed to bind to and inhibit mIDH1 to reduce 2-hydroxyglutarate levels and restore normal cellular differentiation of myeloid cells. The collaboration aims to evaluate the potential of olutasidenib to treat newly diagnosed and relapsed or refractory (R/R) patients with AML, higher-risk myelodysplastic syndromes (MDS), and advanced myeloproliferative neoplasms (MPN), in combination with other agents. The alliance will also support the evaluation of olutasidenib as monotherapy in lower-risk MDS and as maintenance therapy in post-hematopoietic stem cell transplant patients. Rigel will provide $15 million in time-based milestone payments and study material over the five-year collaboration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.67%
Tags
none
-
News
Rigel Reports Third Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) reports Q3 2023 Total Revenue of $28.1 million, including record TAVALISSE® net product sales of $24.5 million and REZLIDHIA® net product sales of $2.7 million. New data on olutasidenib in mIDH1 relapsed or refractory acute myeloid leukemia to be presented at ASH Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.3%
Tags
earnings
-
News
Rigel to Present at the Jefferies London Healthcare Conference
Rhea-AI Summary
Rigel Pharmaceuticals will present a company overview at the Jefferies 2023 London Healthcare Conference on November 14, 2023. The presentation will be given by Dean Schorno, the company's CFO, at 3:30 p.m. GMT. The webcast can be accessed on Rigel's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.55%
Tags
conferences
News
Rigel Announces Poster Presentations at the 65th American Society of Hematology Annual Meeting and Exposition
Rhea-AI Summary
Rigel Pharmaceuticals, Inc. will present data on their hematology-oncology portfolio at the ASH Annual Meeting. The data includes positive results of olutasidenib in mIDH1 AML and MDS patients, showing complete remissions and durable responses. The company is encouraged by the potential use of REZLIDHIA in various patient populations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Rigel Announces Conference Call and Webcast to Report Third Quarter 2023 Financial Results and Business Update
Rhea-AI Summary
Rigel Pharmaceuticals, Inc. will report its third quarter 2023 financial results on November 7, 2023. A live conference call and webcast will follow the announcement to discuss the financial results and provide a business update. Participants can access the conference call and webcast through dial-in numbers or the company's website. The webcast will be available for replay for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
conferences earnings
-
News
Rigel Announces Presentation at the Upcoming IDWeek 2023
Rhea-AI Summary
Rigel Pharmaceuticals provides update on ACTIV-4 Host Tissue trial and upcoming oral presentation on the FOCUS Phase 3 clinical trial of fostamatinib in COVID-19 patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.91%
Tags
none
News
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
Rigel Pharmaceuticals grants stock options to employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Athersys Director Jane Wasman Appointed Board Chair
Rhea-AI Summary
Athersys, Inc. announces changes to its Board of Directors. Jane Wasman appointed as Board Chair. Her expertise in strategic, operational, and corporate governance matters will be valuable. She is also chair of the board of directors of Sellas Life Sciences and a member of the board of directors of Rigel Pharmaceuticals. Positive for shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
none
-
News
Rigel to Present at the 2023 Cantor Global Healthcare Conference
Rhea-AI Summary
Rigel Pharmaceuticals CFO to present at Cantor Global Healthcare Conference on Sep 27, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
News
Rigel to Participate in Upcoming September Investor Conferences
Rhea-AI Summary
Rigel Pharmaceuticals to participate in investor conferences in September
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Stock RIGL logo
Rigel Pharmaceuticals

Nasdaq:RIGL

RIGL Rankings

#3761 Ranked by Market Cap
#1990 Ranked by Stock Gains
N/A Ranked by Dividends

RIGL Stock Data

210.49M
146.96M
2.11%
61.38%
2.86%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
South San Francisco

About RIGL

rigel pharmaceuticals, inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases.